➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Mallinckrodt
Express Scripts
Medtronic
Merck

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

Vicuron Holdings Company Profile


Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for VICURON HOLDINGS, and what generic alternatives to VICURON HOLDINGS drugs are available?

VICURON HOLDINGS has one approved drug.

There are two US patents protecting VICURON HOLDINGS drugs.

There are twenty-one patent family members on VICURON HOLDINGS drugs in seventeen countries and four supplementary protection certificates in four countries.

Summary for Vicuron Holdings
International Patents:21
US Patents:2
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Vicuron Holdings

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vicuron Holdings ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial
Vicuron Holdings ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 RX Yes Yes 6,960,564 ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Vicuron Holdings ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 RX Yes Yes 6,960,564 ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Vicuron Holdings

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Vicuron Holdings ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 6,743,777 ⤷  Free Forever Trial
Vicuron Holdings ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 5,965,525 ⤷  Free Forever Trial
Vicuron Holdings ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 5,965,525 ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for Vicuron Holdings Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0561639 08C0009 France ⤷  Free Forever Trial PRODUCT NAME: ANIDULAFUNGINE; REGISTRATION NO/DATE: EU/1/07/416/001 20070920
0561639 C00561639/01 Switzerland ⤷  Free Forever Trial PRODUCT NAME: ANIDULAFUNGIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58325 03.09.2009
0561639 SPC/GB08/016 United Kingdom ⤷  Free Forever Trial PRODUCT NAME: ANIDULAFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/416/001 20070920
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Mallinckrodt
Baxter
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.